Alaska Permanent Fund Corp Has $3.38 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Alaska Permanent Fund Corp raised its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 74.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 3,846 shares of the biopharmaceutical company's stock after purchasing an additional 1,641 shares during the quarter. Alaska Permanent Fund Corp's holdings in Regeneron Pharmaceuticals were worth $3,378,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in REGN. Ronald Blue Trust Inc. lifted its holdings in shares of Regeneron Pharmaceuticals by 18.8% in the third quarter. Ronald Blue Trust Inc. now owns 76 shares of the biopharmaceutical company's stock worth $63,000 after buying an additional 12 shares in the last quarter. IFP Advisors Inc lifted its holdings in shares of Regeneron Pharmaceuticals by 9.7% in the third quarter. IFP Advisors Inc now owns 442 shares of the biopharmaceutical company's stock worth $364,000 after buying an additional 39 shares in the last quarter. Ritholtz Wealth Management lifted its holdings in shares of Regeneron Pharmaceuticals by 18.3% in the third quarter. Ritholtz Wealth Management now owns 510 shares of the biopharmaceutical company's stock worth $420,000 after buying an additional 79 shares in the last quarter. Global Retirement Partners LLC increased its position in Regeneron Pharmaceuticals by 67.1% in the third quarter. Global Retirement Partners LLC now owns 249 shares of the biopharmaceutical company's stock worth $203,000 after purchasing an additional 100 shares during the last quarter. Finally, Park Place Capital Corp increased its position in Regeneron Pharmaceuticals by 18.8% in the third quarter. Park Place Capital Corp now owns 95 shares of the biopharmaceutical company's stock worth $78,000 after purchasing an additional 15 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company's stock.

Analyst Ratings Changes

Several equities research analysts recently weighed in on REGN shares. Morgan Stanley boosted their price target on shares of Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the stock an "overweight" rating in a research report on Wednesday, March 13th. Cantor Fitzgerald reiterated a "neutral" rating and set a $925.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Monday, April 15th. BMO Capital Markets boosted their price objective on shares of Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the company an "outperform" rating in a research report on Monday, February 5th. Barclays boosted their price objective on shares of Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the company an "overweight" rating in a research report on Tuesday, January 23rd. Finally, Sanford C. Bernstein assumed coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, March 12th. They set an "outperform" rating and a $1,125.00 price objective on the stock. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and sixteen have given a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $977.77.

Insider Activity

In other news, EVP Marion Mccourt sold 1,000 shares of the company's stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $934.71, for a total transaction of $934,710.00. Following the transaction, the executive vice president now owns 13,789 shares in the company, valued at $12,888,716.19. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In related news, EVP Marion Mccourt sold 1,000 shares of the stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $934.71, for a total value of $934,710.00. Following the transaction, the executive vice president now owns 13,789 shares in the company, valued at approximately $12,888,716.19. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP Andrew J. Murphy sold 5,783 shares of the stock in a transaction that occurred on Thursday, March 14th. The stock was sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the completion of the transaction, the executive vice president now owns 48,306 shares in the company, valued at approximately $46,203,239.82. The disclosure for this sale can be found here. Insiders have sold a total of 11,022 shares of company stock worth $10,552,991 over the last 90 days. 8.83% of the stock is currently owned by corporate insiders.

Regeneron Pharmaceuticals Stock Down 0.1 %

Shares of REGN stock traded down $0.78 during mid-day trading on Wednesday, hitting $906.54. 369,734 shares of the stock traded hands, compared to its average volume of 489,809. The stock has a market cap of $99.50 billion, a P/E ratio of 26.09, a P/E/G ratio of 2.59 and a beta of 0.11. The stock's fifty day moving average is $950.58 and its two-hundred day moving average is $893.29. Regeneron Pharmaceuticals, Inc. has a 52-week low of $684.80 and a 52-week high of $998.33. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.69 and a quick ratio of 4.94.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings data on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.73 by $1.13. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. The firm had revenue of $3.43 billion for the quarter, compared to the consensus estimate of $3.29 billion. During the same quarter in the prior year, the company posted $10.96 earnings per share. The company's revenue for the quarter was up .6% compared to the same quarter last year. Equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 38.8 EPS for the current year.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.